Navigation Links
Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
Date:9/11/2013

Mississauga, Ontario (PRWEB) September 11, 2013

Therapure Biopharma Inc. announced today that its biomanufacturing division, Therapure Biomanufacturing, has won the 2013 CMO Leadership Award as a leader in all five categories: Quality, Reliability, Innovation, Productivity and Regulatory.

The CMO Leadership Award is based on the responses of more than 10,000 pharmaceutical and biopharmaceutical executives in a survey conducted by Nice Insight and presented by Life Science Leader Magazine. The award recognizes contract manufacturing organizations that achieve customer perception scores in the top 20% in the five industry-driven categories.

In accepting the 2013 award, Therapure Biopharma Inc. President and Chief Executive Officer, Mr. Nick Green said, “It is an honor to be recognized for a 3rd consecutive year for the CMO Leadership Award, and once again in all five categories. This award recognizes the diligence, passion and contribution of our employees who strive to meet our clients’ needs and produce the highest quality therapeutics possible. The 5 categories are critical to our clients’ success and more importantly for patient well being.”

Theapure Biomanufacturing will be recognized as an award winner in the annual CMO Leadership Awards supplement published by Life Science Leader in October.

To meet the Therapure Contract Development and Manufacturing Organization (CDMO) team and discuss how they can help you with your biomanufacturing needs, they invite you to visit Therapure at the:

  •     BioProcess International conference, Booth 906, September 17–19th, 2013, in Boston, MA
  •     ContractPharma conference, Booth 10, September 19th, 2013, in New Brunswick, NJ.

Therapure Biopharma Inc. is also pleased to announce the launch of its new website, found at http://www.therapurebio.com. The new website, designed with a fresh new look and user-friendly navigation, reflects the unique business structure of the organization, which is comprised of Therapure Biomanufacturing (http://www.therapurebio.com/CDMO) the award-winning CDMO division, and Therapure Innovations (http://www.therapurebio.com/innovations), the proprietary drug pipeline and platform technology research and development division.

About Therapure Biomanufacturing
Therapure Biomanufacturing is a global contract development and manufacturing organization (CDMO) offering integrated services for developing, manufacturing, purifying and packaging complex biological therapeutics. Our scientific and manufacturing expertise, as well as our flexible state-of-the-art cGMP facility, provides clients with optimal biomanufacturing solutions to advance their biotherapeutics from discovery to market.

About Therapure Biopharma Inc.
Therapure Biopharma Inc. is an integrated biopharmaceutical company focused on complex biological therapeutics and technologies that can provide new options for patient care. It is comprised of Therapure Biomanufacturing, the award-winning CDMO division and Therapure Innovations, the proprietary drug pipeline and platform technology research and development division. Therapure Biopharma Inc.’s 130,000 sq. ft. cGMP facility includes biomanufacturing, research and quality-control laboratories and is built to meet FDA (USA), HPFB (Canada), EMA (Europe) and MHRA (UK) standards.

For more information, please visit http://www.therapurebio.com
Company Contact:
Dina Iezzi
Director, Marketing and Special Projects
diezzi(at)therapurebio(dot)com
905-286-6270

Read the full story at http://www.prweb.com/releases/2013/9/prweb11111116.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
3. CeNeRx BioPharma Completes $4.85 Million Financing
4. PDL BioPharma Completes Regular Quarterly Dividend Payment
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
7. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
10. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
11. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/28/2016)... The report "Cryocooler Market by ... (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, and ... 2022", published by MarketsandMarkets, the global market is expected ... a CAGR of 7.29% between 2016 and 2022. ... Figures spread through 159 Pages and in-depth TOC on ...
(Date:4/28/2016)... Connecticut (PRWEB) , ... April 28, 2016 , ... ... Group, Inc., will hold an open house for regional manufacturers at its Maple ... displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading ...
(Date:4/27/2016)... VANCOUVER, British Columbia , April 27, 2016 ... "Gesellschaft" oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... sie im Anschluss an ihre Pressemitteilung vom 13. ... Inc. erhalten hat, ihre Finanzen um zusätzliche 200.000.000 ... auf 4.000.000 Kanadische Dollar zu bringen. Davon wurden ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):